Gilead Sciences Touts Encouraging Data From Real World Studies Of Its Flagship COVID-19 Treatment

Gilead Sciences Inc GILD announced data from three retrospective real-world Veklury (remdesivir) studies for COVID-19 treatment.
The studies demonstrated that initiating Veklury within the first two days of hospital admission can help reduce mortality and hospital readmission rates among all patients hospitalized with COVID-19, regardless of disease severity.
A reduction in mortality was also observed in vulnerable populations.
Related: WHO Recommends Gilead's COVID-19 Therapy For Severe Disease.
Two studies analyzed clinical practice information from the U.S. Premier Healthcare databases of more than 500,000 adult patients hospitalized with COVID-19.
For patients with no documented use of supplemental oxygen at baseline, treatment with Veklury was associated with a 19% lower risk of mortality at Day 28.
Patients on low-flow or high-flow oxygen also had a 21% and 12% lower mortality risk at Day 28, respectively.
Patients on invasive mechanical ventilation/ECMO at baseline had a 26% reduced risk for mortality at Day 28.
These findings were observed throughout all variant periods, including Omicron, in patients who did not require supplemental oxygen and across all levels of supplemental oxygen use.
A separate analysis found that hospitalized patients with COVID-19 treated with Veklury were also significantly less likely (27%) to be readmitted within 30 days to the same hospital.
Based on in vitro analyses, Veklury retains potent antiviral activity against recent Omicron subvariants of concern.
Price Action: GILD shares are down 0.38% at $84.32 on the last check Wednesday.